The UAE has become the second country in the world to approve the new lung cancer drug 'Lumakras'.
The Ministry of Health and Prevention (MoHAP) has cleared the registration and use of the drug, which recently received the approval of the US Food and Drug Administration (FDA).
It will help speed up the treatment plan of patients in the UAE and improve their quality of life.
Lumakras, manufactured by Amgen, is prescribed to adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one previous cancer therapy.
It is supplied as film-coated tablets for oral use containing 120 mg of sotorasib.
UAE expresses solidarity with Greece over death of two pilots in plane crash
H.H. Sheikh Mohammed pays tribute to UAE President in personal message
UAE joins 7 other countries in rejecting displacement of Palestinians from Gaza
Five UAE aid convoys enter Gaza carrying 533 tonnes of supplies
UAE search and rescue team begins field operations in flood-hit Nepal
Dubai Police completes 104 technology projects in a year
UAE leaders meet with King of Bahrain to discuss regional issues
New RTA development at Al Qiyadah Intersection cuts traffic by 15 per cent
